Corsmed is a technology company.
Corsmed has raised $4.0M across 1 funding round.
Corsmed has raised $4.0M in total across 1 funding round.
Corsmed has raised $4.0M in total across 1 funding round.
Corsmed's investors include Alpha Edison, Altair Capital Management, BoxGroup, Brainchild, Cherry Ventures, Cota Capital, Giza Polish Ventures, Great Oaks Venture Capital, Jonathan Becker, Luminar Ventures, Neu Venture Capital, NFX.
Corsmed is a Stockholm-based MedTech startup developing software-only solutions for MRI simulation and acceleration, enabling faster, cheaper, and more accessible MRI training and scanning.[1][2][3] Its core products include a web-based MRI simulator for hands-on training—accessible from any laptop without installations—and advanced research-driven software that reduces scan times from 45 minutes to 2-3 minutes using digital twin technology and quantitative imaging.[1][2][5][6] Serving universities, hospitals, and research institutions like the UK's NHS, The Christie NHS Foundation Trust, and Lund University, Corsmed addresses training bottlenecks and diagnostic delays, improving technologist proficiency, patient outcomes, and preventive healthcare scalability.[1][2][6] With 11-50 employees and recent €3.3 million funding, the company shows strong growth momentum toward FDA/HIPAA compliance and global commercialization.[2][7]
Corsmed emerged from over 10 years of academic research in MRI optimization, with conflicting founding dates reported as 2016 or 2019; the later date aligns with its startup phase led by CEO Erik Jacobsson, CTO Christos Xanthis, and CSO Athanasios Polimeridis.[1][2][5] The founders leveraged their expertise to create simulation tools initially for education, gaining early traction with institutions like CNI College and Gurnick Academy.[1][2] A pivotal moment came with breakthroughs in AI-accelerated digital twin technology, enabling 10x faster 3D brain scans while retaining resolution, which propelled the company from simulation-focused training to clinical-grade software for throughput improvements.[2][5] This evolution reflects a shift from risk-free training platforms to revolutionary scanning efficiency, fueled by published studies and stealth R&D.[5][6]
Corsmed rides the convergence of AI, quantitative imaging, and preventive healthcare trends, where MRI bottlenecks—long scans, high costs, and training shortages—limit global diagnostics amid rising demand.[2][3][5] Its timing capitalizes on post-pandemic telehealth acceleration and AI imaging booms, enabling 10x cheaper, faster scans that democratize access for early detection of conditions like cancer.[2] Market forces like aging populations and scanner backlogs (e.g., in NHS systems) favor software retrofits over hardware overhauls, positioning Corsmed to influence ecosystems by upskilling technologists at scale and feeding superior data to AI models for personalized medicine.[1][2][6] Investors like Luminar Ventures highlight its potential to save lives daily through exponential improvements in throughput and affordability.[2]
Corsmed is poised to disrupt MRI from training to clinical deployment, with €3.3 million fueling U.S. regulatory approvals, HIPAA compliance, and global sales—unlocking preventative health at scale.[2] Trends like AI-driven imaging and quantitative MRI will amplify its edge, potentially expanding to full-body protocols and integrated AI pipelines for real-time analysis. Its influence may evolve from niche simulator to industry standard, reshaping diagnostics as hardware-agnostic software dominates MedTech, ultimately making "faster, cheaper, better MRI for everyone" a reality.[3]
Corsmed has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $4.0M Seed | Alpha Edison, Altair Capital Management, BoxGroup, Brainchild, Cherry Ventures, Cota Capital, Giza Polish Ventures, Great Oaks Venture Capital, Jonathan Becker, Luminar Ventures, Neu Venture Capital, NFX, Obvious Ventures, Techstars, Vayner RSE, Elad Kushnir, Joe Greenstein |